ClinicalTrials.gg
CompletedNCT06717100Updated Aug 13, 2026Results posted

Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib

A Phase 1 interventional study of Nintedanib 150 MG [Ofev] in Drug Interactions, sponsored by PureTech. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by PureTech · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Pulmonary Fibrosis with a site in Australia — 5 open to participants now, 10 under way, 3 of them phase 3. Pulmonary Fibrosis · Australia.

Enrollment
22nd of 24
24 · median 206
Started
2024
with 3 others
Phase 1
4 of 26
none open now
Registered
24th of 26
by date

Among the 26 studies in Pulmonary Fibrosis with a site in Australia, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2024, is one of 4 in phase 1, and was the 24th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

5 of the 26 studies in Pulmonary Fibrosis with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pulmonary Fibrosis with a site in Australia, or all of them as a file.
02

Study summary

This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .

Read the detailed description

The purpose of this research is to investigate the effects of deupirfenidone (LYT-100) when co-administered with nintedanib to determine if there are any drug-drug interactions. In particular, the study will investigate the safety, tolerability and pharmacokinetics of LYT-100 co-administered with nintedanib. Eligible participants will be admitted to the Clinical Research Unit for 31 days, will be administered nintedanib and/or LYT-100 for 30 days, and will provide blood samples and have assessments during this time. Participants will return for a safety follow-up visit 30 days after taking the last dose of study drug.

03

Conditions studied

  • Drug Interactions

Keywords

  • LYT-100
  • nintedanib
  • deupirfenidone
  • drug interaction
  • interaction
  • Pulmonary Fibrosis
  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provides written Ethics Committee approved prior to any study procedures.
  2. Male or female between 18 and 65 years old (inclusive) at the time of Screening.
  3. In good general health at Screening, free from unstable and/or acute medical, surgical or psychiatric illness/es and a full physical examination, at the discretion of the Investigator.
  4. Clinical laboratory analytes at Screening and Day -1 (including hematology, biochemistry, coagulation, and urinalysis) within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI.
  5. Subjects have a (BMI) between ≥ 18.0 and ≤ 35.0 kg/m2 and weigh at least 50 kg at Screening.
  6. Vital signs (measured in sitting position after 5 minutes' rest) at Screening and at Day -1:

    1. Systolic blood pressure ≥90 and ≤140 mmHg; and
    2. Diastolic blood pressure ≥40 and ≤ 90 mmHg; and
    3. Heart rate ≥40 and ≤100 beats per minute (bpm). Note: If vital signs are out of range, the Investigator may obtain one additional reading, so that up to 2 consecutive assessments are made within 1 hour and with the subject seated quietly during the 5 minutes preceding the assessment.
  7. Adequate venous access in the left or right arm to allow collection of multiple blood samples.
  8. No relevant dietary restrictions, and willing to consume the entirety of the standard meals provided.
  9. Willing to comply with all study procedures and requirements.
  10. Willing to abstain from direct whole body sun exposure from 2 days prior to dosing and until EOS/Follow-up Visit.
  11. Women of (WOCBP) must be non-pregnant and non-lactating, and must use acceptable, highly effective or be abstinent from heterosexual intercourse if this is their usual sexual practice from Screening until study completion, including the follow-up period and an additional 90 days after the last dose of study drug. Effective forms of contraception are defined in Section 4.4.4 of the protocol. WOCBP must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Day -1 and be willing to have additional pregnancy tests as required throughout the study.
  12. Women not of childbearing potential must be post menopausal for ≥12 months (without an alternative medical cause) or be surgically sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy). status will be confirmed through testing of follicle stimulating hormone (FSH) levels ≥ 40 IU/L at Screening. Bilateral tubal ligation is acceptable (if completed successfully and done at least one year prior to Screening [verbal confirmation is permitted]), but condom use by male partner is required until study completion including the follow-up period.
  13. Male subjects must be surgically sterile (> 90 days since vasectomy with no viable sperm confirmed by laboratory documentation), abstinent if this is their usual sexual practice, or if engaged in sexual relations with a WOCBP, the subject and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method (See Section 4.4.4 of the protocol) from Screening until study completion, including the follow-up period and an additional 90 days after the last dose of study drug. Male subjects that have undergone a vasectomy must use a condom from Screening until study completion, including the follow-up period and an additional 90 days after the last dose of study drug.
  14. Males must not donate sperm and females must not donate ova or oocytes (i.e., human eggs) for at least 90 days after the last dose of study drug.
  15. Subjects with same-sex partners (abstinence from penile-vaginal intercourse) or who are abstinent from heterosexual intercourse are not required to use contraception when this is their preferred and usual lifestyle.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating at Screening or Day -1 or planning to become pregnant (self or partner) at any time during the study, including the specified follow-up period.
  2. History or presence of at Screening or Day -1, with the exception of adequately treated localised skin cancer (basal cell or squamous cell carcinoma) or carcinoma in-situ of the cervix.
  3. History of migraine, whether treated or untreated, within 3 years prior to Screening
  4. infection within 28 days of the start of dosing, or infections requiring parenteral antibiotics within the 6 months prior to Screening.
  5. Clinically significant surgical procedure within 3 months of Screening, at the discretion of the Investigator, or any planned significant surgical procedure prior to the EOS/Follow-up visit.
  6. Family history (biological relatives [i.e., parents, siblings]) of long or short syndrome, or Torsades de Pointes.
  7. Currently suffering from clinically significant systemic allergic disease at Screening or Day -1 or has a history of significant drug allergies including a history of anaphylactic reaction; allergic reaction due to any drug which led to significant morbidity; prior allergic reaction to pirfenidone.
  8. Chronic administration (defined as more than 14 consecutive days) of or other immune-modifying drugs within 3 months prior to study drug administration; are permitted at the discretion of the Investigator). Topical agents are not exclusionary.
  9. History or presence at Screening or Day -1 of a condition associated with significant immunosuppression.
  10. Positive result of a RT-qPCR diagnostic test for SARS-CoV-2 at Screening or Day -1.
  11. Positive test for antibody (HCV), surface antigen (HBsAg), or (HIV) antibody at Screening. Subjects who are positive for HCVAb will be tested for hepatitis C ribonucleic acid (HCV RNA) by polymerase chain reaction (PCR) and, if HCV RNA PCR is positive, will be excluded.
  12. Symptoms of dysphagia at Screening or Day -1 or known difficulty in swallowing capsules.
  13. History or presence of gastrointestinal (including a previous episode of pancreatitis), hepatic or renal disease, or any other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  14. Any condition at Screening or Day -1 (e.g., chronic diarrhoea, inflammatory bowel disease or prior surgery of the gastrointestinal tract) that would interfere with drug absorption or any disease or condition that is likely to affect drug metabolism or excretion, at the discretion of the Investigator.
  15. History or presence at Screening or Day -1 of cardiac arrhythmia or congenital long QT syndrome.
  16. QT interval corrected using Fridericia's formula (QTcF) > 450 msec (male) or 470 msec (female) demonstrated by two ECGs 30 to 60 minutes apart at Screening or Day -1 visits. The average of the 2 QTcF intervals should be used to determine the subject's eligibility.
  17. Use of smoked tobacco or nicotine containing products in the previous 3 months prior to dosing or use of other tobacco or nicotine containing products in the previous 2 weeks prior to dosing, or a positive urine cotinine test at Screening or Day -1.
  18. Lack of willingness to abstain from the consumption of tobacco or nicotine-containing products throughout the duration of the study and until the EOS/Follow-up visit.
  19. Lack of willingness to abstain from the use of alcohol throughout the study (Treatment through EOS/Follow-up visit).
  20. Positive toxicology screening panel (urine test, including qualitative identification of barbiturates, tetrahydrocannabinol [THC], amphetamines, benzodiazepines, opiates and cocaine) or alcohol breath test at Screening or Day -1, at any time during the Study. One repeat urine toxicology screen may be conducted, within 48 h of the first, if the first is considered by the Investigator to be invalid.
  21. History of substance abuse or dependency or history of recreational intravenous (IV) drug use, over the last 2 years.
  22. Use of any prescription drugs, over the counter (OTC) medication, nonsteroidal anti-inflammatory agents (NSAIDs), herbal remedies, supplements or vitamins within the 14 days prior to dosing or throughout the duration of the study, without prior approval of the Investigator and written approval of the Medical Monitor.
  23. Paracetamol/acetaminophen may be utilised, provided that the dose of paracetamol does not exceed 2 g in any 24 h period.
  24. Use of any of the any drugs listed in Section 4.4.1 within 28 days or 5 half-lives of that drug, whichever is longer, prior to study drug administration.
  25. Vaccination with a within the 4 weeks prior to Screening or that is planned prior to the EOS visit, and any non-live vaccination within the 2 weeks prior to Screening or that is planned within 2 weeks of dosing (including those for COVID-19)
  26. Exposure to any significantly immune suppressing drug within the 3 months prior to Screening or 5 half lives, whichever is longer.
  27. Use of any drug or device within 3 months prior to Screening.
  28. Consumption of soy, grapefruit, grapefruit juice, Seville oranges, Seville orange juice, or any foods containing these ingredients, within 7 days prior to dosing until 24 hours after the final dose of study drug or unwilling to abstain from these throughout the duration of the study, until the EOS visit.
  29. Clinically significant blood loss, blood or blood product donation >250 mL within 28 days of Screening.
  30. Subject is unwilling to refrain from strenuous exercise which significantly exceeds the subject's usual level of physical activity from 48 h prior to admission to the clinical trial unit and until completion of the final onsite follow-up visit, where strenuous exercise is defined as a significant increase in the Subject's usual level of physical activity or lifting weights or running uphill.
  31. Any other reason that, in the opinion of the Investigator, might interfere with the evaluation required by the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    DDI Cohort

    All participants will receive the same interventions at the same schedule

    Drug: Nintedanib 150 MG [Ofev]

Interventions

  • Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.

    Also known as: Deupirfenidone (LYT-100) 275 MG

06

What researchers measure

Primary outcomes

  1. AUC of LYT-100 and Nintedanib

    The area under the curve will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.

    Time frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100

  2. Tmax of LYT-100 and Nintedanib

    The time to maximum concentration (Tmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.

    Time frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100

  3. Cmax of LYT-100 and Nintedanib

    The maximum observed plasma concentration (Cmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.

    Time frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100

Secondary outcomes

  1. Number of Subjects With Abnormal Vital Signs (Blood Pressure)

    Systolic and Diastolic blood pressure measured in millimeters of mercury (mmHg) to determine if there is abnormal blood pressure

    Time frame: Screening through Follow-up Visit on Day 60

  2. Number of Subjects With Abnormal Vital Signs (Heart Rate)

    Heart rate is measured in beats per minute (bpm) to determine if there is an abnormal heart rate

    Time frame: Screening through Follow-up Visit on Day 60

  3. Number of Subjects With Abnormal Vital Signs (Respiration Rate)

    Respiration rate is measured in breaths per minute (bpm) to determine if the respiration rate is abnormal

    Time frame: Screening through Follow-up Visit on Day 60

  4. Number of Subjects With Abnormal Vital Signs (Body Temperature)

    Tympanic body temperature is measured in degrees Celsius to determine if the body temperature is abnormal

    Time frame: Screening through Follow-up Visit on Day 60

  5. Number of Subjects With Abnormal Electrocardiograms

    Number of participants with an abnormal ECG and/or that have a QTcF\>450 ms

    Time frame: Screening through Follow-up Visit on Day 60

  6. Number of Subjects With Abnormal Physical Examinations

    A physical examination is performed to determine if any physical abnormalities are detected

    Time frame: Screening through Follow-up Visit on Day 60

  7. Number of Subjects With Abnormal Laboratory Values (Hematology)

    Hematology parameters to be tested are hemoglobin, hematocrit, erythrocytes, platelets, and leukocytes.

    Time frame: Screening through Follow-up Visit on Day 60

  8. Number of Subjects With Abnormal Laboratory Values (Serum Chemistry)

    Serum chemistry parameters to be tested are C-reactive protein, urea, creatinine, total and direct bilirubin, urate, albumin, globulin, alkaline phosphatase, creatine phosphokinase, troponin 1, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate

    Time frame: Screening through Follow-up Visit on Day 60

  9. Number of Subjects With Abnormal Laboratory Values (Coagulation)

    Coagulation parameters to be tested are international normalized ratio, prothrombin time, activated partial thromboplastin time

    Time frame: Screening through Follow-up Visit on Day 60

  10. Number of Subjects With Abnormal Laboratory Values (Urinalysis)

    Urinalysis parameters to be tested are micro protein, nitrite, pH, trial specific gravity, ketone bodies, urobilinogen, blood, urine leukocyte esterase, appearance uri acm, micro glucose, bilirubin

    Time frame: Screening through Follow-up Visit on Day 60

07

Results

Posted Aug 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneDDI Cohort
Started24
Nintedanib 150 mg (days 1 to 7)24
Nintedanib+lyt-100 (days 8 to 20)24
Lyt-100 (days 21 to 30)24
Completed24
Not completed0

Outcome measures

PrimaryAUC of LYT-100 and Nintedanib

The area under the curve will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.

Time frame:
Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
Reported as:
Mean · (h*ng/mL)
AUC of LYT-100 and Nintedanib
(h*ng/mL)A. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
AUC of LYT-100 and Nintedanib206 ± 105257 ± 13237410 ± 16726246 ± 12354348 ± 1911851998 ± 17709
PrimaryTmax of LYT-100 and Nintedanib

The time to maximum concentration (Tmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.

Time frame:
Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
Reported as:
Median · hours
Tmax of LYT-100 and Nintedanib
hoursA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Tmax of LYT-100 and Nintedanib2.50 ± 05.92 ± 02.00 ± 02.50 ± 02.00 ± 02.00 ± 0
PrimaryCmax of LYT-100 and Nintedanib

The maximum observed plasma concentration (Cmax) will be calculated from the first observed to last measurable plasma concentration. For nintedanib, dosing begins on Day 1 and ends on Day 20. For LYT-100, dosing begins on Day 8 and ends on Day 30.

Time frame:
Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
Reported as:
Mean · ng/mL
Cmax of LYT-100 and Nintedanib
ng/mLA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Cmax of LYT-100 and Nintedanib36.1 ± 20.338.7 ± 22.08845 ± 350037.2 ± 18.912669 ± 360612581 ± 3371
SecondaryNumber of Subjects With Abnormal Vital Signs (Blood Pressure)

Systolic and Diastolic blood pressure measured in millimeters of mercury (mmHg) to determine if there is abnormal blood pressure

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Vital Signs (Blood Pressure)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Vital Signs (Blood Pressure)000000
SecondaryNumber of Subjects With Abnormal Vital Signs (Heart Rate)

Heart rate is measured in beats per minute (bpm) to determine if there is an abnormal heart rate

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Vital Signs (Heart Rate)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Vital Signs (Heart Rate)000000
SecondaryNumber of Subjects With Abnormal Vital Signs (Respiration Rate)

Respiration rate is measured in breaths per minute (bpm) to determine if the respiration rate is abnormal

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Vital Signs (Respiration Rate)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Vital Signs (Respiration Rate)000000
SecondaryNumber of Subjects With Abnormal Vital Signs (Body Temperature)

Tympanic body temperature is measured in degrees Celsius to determine if the body temperature is abnormal

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Vital Signs (Body Temperature)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Vital Signs (Body Temperature)000000
SecondaryNumber of Subjects With Abnormal Electrocardiograms

Number of participants with an abnormal ECG and/or that have a QTcF\>450 ms

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Electrocardiograms
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Electrocardiograms000000
SecondaryNumber of Subjects With Abnormal Physical Examinations

A physical examination is performed to determine if any physical abnormalities are detected

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Physical Examinations
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Physical Examinations000000
SecondaryNumber of Subjects With Abnormal Laboratory Values (Hematology)

Hematology parameters to be tested are hemoglobin, hematocrit, erythrocytes, platelets, and leukocytes.

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Laboratory Values (Hematology)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Laboratory Values (Hematology)000000
SecondaryNumber of Subjects With Abnormal Laboratory Values (Serum Chemistry)

Serum chemistry parameters to be tested are C-reactive protein, urea, creatinine, total and direct bilirubin, urate, albumin, globulin, alkaline phosphatase, creatine phosphokinase, troponin 1, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Laboratory Values (Serum Chemistry)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Laboratory Values (Serum Chemistry)100001
SecondaryNumber of Subjects With Abnormal Laboratory Values (Coagulation)

Coagulation parameters to be tested are international normalized ratio, prothrombin time, activated partial thromboplastin time

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Laboratory Values (Coagulation)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Laboratory Values (Coagulation)000000
SecondaryNumber of Subjects With Abnormal Laboratory Values (Urinalysis)

Urinalysis parameters to be tested are micro protein, nitrite, pH, trial specific gravity, ketone bodies, urobilinogen, blood, urine leukocyte esterase, appearance uri acm, micro glucose, bilirubin

Time frame:
Screening through Follow-up Visit on Day 60
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Laboratory Values (Urinalysis)
ParticipantsA. Nintedanib 150 mg (Days 1 to 7)C. Nintedanib 150 mg (Days 11 to 13)C. LYT100 550 mg (Days 11 to 13)D. Nintedanib 150mg (Days 14 to 20)D. LYT100 825 mg (Days 14 to 20)E. LYT100 825 mg (Days 21 to 30)
Number of Subjects With Abnormal Laboratory Values (Urinalysis)000000

Adverse events

Collected over Screening through Follow-up Visit on Day 60. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib 150 mg q12h (Days 1 to 7)0/24 (0%)0/24 (0%)7/24 (29.2%)
Nintedanib + LYT-100 150 mg q12h + TID (Days 8 to 20)0/24 (0%)0/24 (0%)17/24 (70.8%)
LYT-100 825 mg TID (Days 21 to 30)0/22 (0%)0/22 (0%)10/22 (45.5%)
Overall0/24 (0%)0/24 (0%)21/24 (87.5%)
Most frequent other events
Showing 10 of 34
Most frequent other events
EventNintedanib 150 mg q12h (Days 1 to 7)Nintedanib + LYT-100 150 mg q12h + TID (Days 8 to 20)LYT-100 825 mg TID (Days 21 to 30)Overall
NauseaGastrointestinal disorders3/2410/242/2214/24
HeadacheNervous system disorders2/246/244/229/24
Abdominal PainGastrointestinal disorders2/245/241/227/24
DiarrhoeaGastrointestinal disorders3/244/240/227/24
DyspepsiaGastrointestinal disorders0/245/242/225/24
VomitingGastrointestinal disorders1/241/241/223/24
PresyncopeNervous system disorders0/242/241/223/24
DizzinessNervous system disorders0/242/240/222/24
Upper respiratory infectionsInfections and infestations1/241/240/222/24
Aphthous ulcerGastrointestinal disorders0/240/241/221/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DDI Cohort
<=18 years0
Between 18 and 65 years24
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)DDI Cohort
Female3
Male21
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DDI Cohort
American Indian or Alaska Native1
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American0
White13
More than one race0
Unknown or Not Reported2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DDI Cohort
Hispanic or Latino1
Not Hispanic or Latino22
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)DDI Cohort
Australia24
08

Study locations

1 site
  • Nucleus Network Pty Ltd (Commercial Rd and St Kilda Rd) - VIC
    Melbourne, Victoria 3004, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Feb 2025, 2 months.

Results were first posted in Aug 2026, 1 year 5 months after primary completion.

Of 20 phase 1 interventional studies under Pulmonary Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 55. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Dec 4, 2024
StartActual
Dec 17, 2024
Primary completionActual
Feb 17, 2025
CompletionActual
Mar 17, 2025
Results first posted
Aug 13, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06717100
Lead sponsor
PureTech
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Dec 17, 2024
Primary completion
Feb 17, 2025
Completion
Mar 17, 2025
Results posted
Aug 13, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion